Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brofaromine in endogenous depression

W M Verhoeven1

  • 1Department of Biological Psychiatry, Vincent van Gogh Institute for Psychiatry, Venray, The Netherlands.

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Verminderde vergrijzing en M. Korsakov; toeval of een voorbeeld van serendiptisme?

Acta neuropsychiatrica·2016
Same author

Klinefelter syndroom en psychiatrische stoornissen: Twee gevalsbeschrijvingen en een literatuuroverzicht.

Acta neuropsychiatrica·2016
Same author

Chronicity, genes en behavior.

Acta neuropsychiatrica·2016
Same author

Neurobiology or agression and impulsivity.

Acta neuropsychiatrica·2016
Same author

Therapeutic drug monitoring.

Acta neuropsychiatrica·2016
Same author

Integratie van opleiding en onderzoek in de opleiding tot psychiater.

Acta neuropsychiatrica·2016

New reversible monoamine oxidase-A (MAO-A) inhibitors like brofaromine show antidepressant effects in patients with endogenous depression. This novel MAO-A inhibitor may benefit those unresponsive to traditional treatments.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • A new class of monoamine oxidase (MAO) inhibitors selectively and reversibly targets MAO-A.
  • These agents represent a potential advancement in psychopharmacology.

Purpose of the Study:

  • To evaluate the efficacy and safety of brofaromine, a selective reversible MAO-A inhibitor.
  • To assess brofaromine's potential in treating endogenous depression.

Main Methods:

  • Administration of brofaromine to subjects with endogenous depression.
  • Monitoring for antidepressive efficacy and adverse events.

Main Results:

  • Brofaromine demonstrated antidepressive efficacy in a majority of treated subjects.
  • The compound was generally well-tolerated, with no serious adverse events reported.

Related Experiment Videos

Conclusions:

  • Brofaromine shows promise as an effective treatment for endogenous depression.
  • It may be a viable option for patients who do not respond to tricyclic antidepressants.